

The Examiner, while still rejecting claims 29-30, 15-16 and 23-28 as unpatentable over the Merck Index in view of Grimminger et al., has indicated that the comparative data presented in the prior response would be persuasive if presented in a Rule 132 declaration of the applicants or other expert in the art. By implication, the presentation of such declaration would constitute reason for allowance of these remaining claims.

In view of the above, a declaration under Rule 132, of Dr. Richard Reichl, one of the applicants, is provided herewith. This declaration presents the comparative data presented in the prior response.

It is earnestly hoped that the presentation of this data in the form of Dr. Reichl's declaration will facilitate the allowance of all remaining claims and of the application as a whole.

The Examiner is urged to contact the undersigned attorney for applicants by telephone should any remaining issues stand in the way of allowance of this application.

Respectfully submitted,



Alan Stempel
Reg. No. 28,991

September 18, 1996
Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
Ridgefield, CT 06877
Tel: 203-798-4868